CT-guided biopsy market to reach $1.06 billion by 2030

The global computed tomography-guided biopsy market is projected to grow from $0.77 billion in 2025 to $1.06 billion by 2030, driven by rising cancer cases, wider use of minimally invasive diagnostics and expanding imaging infrastructure. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - CT-guided biopsy is becoming a core tool for tissue diagnosis as cancer rates rise and clinicians push for more precise, less invasive procedures. - The market’s growth reflects demand for faster confirmation of tumors, infections and inflammatory disease, especially in hard-to-reach organs. - The trend matters for hospitals, outpatient centers and interventional radiology teams that are expanding image-guided diagnostic capacity.

What happened: - The Business Research Company released a market report on the computed tomography-guided biopsy sector. - The report projects the market will grow from $0.77 billion in 2025 to $0.82 billion in 2026. - The report forecasts the market will reach $1.06 billion by 2030. - The report estimates a 6.4% compound annual growth rate for the historical period and 6.6% CAGR for the forecast period. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The report is available through the company's announcement and offers a free sample.

The details: - CT-guided biopsy uses real-time CT imaging to direct a biopsy needle into a targeted area of the body. - The procedure is minimally invasive and is designed to improve targeting accuracy while reducing damage to nearby healthy tissue. - CT-guided biopsy is used to collect tissue samples for histopathological examination. - The procedure is used to assess abnormalities including tumors, infections and inflammatory conditions. - The report ties historical growth to rising global cancer burden, broader use of imaging diagnostics, hospital radiology infrastructure and improved access to CT systems. - The forecast period is supported by early cancer detection, precision medicine diagnostics, outpatient diagnostic centers, aging populations and advances in biopsy needles and procedural safety. - The report highlights growing use of minimally invasive diagnostic techniques and higher demand for image-guided interventions in oncology and infection diagnosis. - The report also points to stronger adoption of outpatient biopsy procedures, growth in interventional radiology departments and more emphasis on tissue-based diagnostics in clinical workflows.

Between the lines: - Cancer incidence is the main demand driver because CT-guided biopsy helps confirm disease in deep or anatomically difficult lesions where imaging alone is not enough. - The procedure is especially important for organs such as the lung, liver, pancreas, kidney and bone. - The International Agency for Research on Cancer reported nearly 20 million new cancer cases and close to 10 million cancer-related deaths worldwide in 2022. - The agency projected annual new cancer cases could reach 35 million by 2050, a 77% increase from 2022. - The report’s expanded analytics package suggests vendors are being pushed to compete on market positioning, forecasting quality and technology differentiation.

What's next: - Growth is likely to track further adoption of outpatient biopsy workflows and interventional radiology services. - Technological improvements in needles and procedural safety should continue to shape the market outlook. - Rising demand for early cancer screening and precision diagnostics is likely to keep image-guided biopsy in focus across healthcare systems.

The bottom line: - CT-guided biopsy is moving from a specialized procedure toward a more essential diagnostic pathway as cancer burden rises and healthcare providers favor precise, minimally invasive testing.